Viking Therapeutics' weight-loss tablet shows promise in small study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Viking Therapeutic (VKTX) PT Raised to $125 at BTIG
March 26, 2024 11:20 AM EDTBTIG analyst Justin Zelin raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $125.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "Viking is up +~25% (vs +0.75% XBI) this morning following presentation of impressive first in human data for oral VK2735, demonstrating 3.3% pbo adj weight loss in the highest dose cohort (40mg QD, n=7) at 28-days with an... More
